We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Aripiprazole Oral Acceptability Trial

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00101569
First Posted: January 13, 2005
Last Update Posted: November 8, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Otsuka America Pharmaceutical
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
January 12, 2005
January 13, 2005
November 8, 2013
March 2004
March 2005   (Final data collection date for primary outcome measure)
acceptability
Not Provided
Complete list of historical versions of study NCT00101569 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Aripiprazole Oral Acceptability Trial
Aripiprazole Oral Acceptability Trial
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Schizophrenia
  • Drug: Aripiprazole
    Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
    Other Name: Abilify
  • Drug: Aripiprazole
    Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
    Other Name: Abilify
  • Experimental: A1
    Intervention: Drug: Aripiprazole
  • Experimental: A2
    Intervention: Drug: Aripiprazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
59
March 2005
March 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Stable patients currently receiving aripiprazole or other antipsychotic medications.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00101569
CN138-091
Not Provided
Not Provided
Not Provided
Not Provided
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Otsuka Pharmaceutical Development & Commercialization, Inc.
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP